In this section
Von Willebrand disease
Ref: White GC et al. Definitions in Hemophilia: Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560
Notify Haem Inpatient Registrar (pager 5030) of patients presenting to Emergency between 0900-1700hrs, Monday to Friday. Notify Haematologist on call of patients presenting after hours with bleeding problems.
Recombinant clotting factor concentrates are the product of choice. Occasionally patients will be treated with plasma-derived concentrates for management of factor VIII/IX inhibitors.
Note that there are two recombinant Factor VIII (FVIII) products available. Whilst it is recommended that patients maintain treatment with their established brand of FVIII product, in an emergency situation administration of any brand of recombinant FVIII is acceptable.
Product name (Brand)
EMR problem list will indicate patient's treatment product.
Plasma derived FVIII(8) and von Willebrand Factor
Instructions for preparation and administration of clotting factor concentrates
Recommended dosage of Haemophilia inhibitor Bypass Agents:
For muscle and joint bleeds R.I.C.E.S will limit bleeding and reduce pain. Initiate on arrival.